News
Four new articles from the NIH Technology Transfer Community have been published in the most recent edition of les Nouvelles, the Licensing Executive Society’s journal. NIH is not just a funder of science but is a critical catalyst that helps transform bold ideas into treatments that reach patients
Are you interested in achieving commercial success with NIH as a strategic partner? Michael Salgaller of the National Cancer Institute (NCI) is leading a workshop at the MedInvest Oncology Investor Conference on how to partner with NIH to bring one of over 2,000 available inventions to market. This
Register to attend a free webinar to assess co-developing an NCI technology. Attendees will learn about new antibodies developed at the National Cancer Institute in the laboratory of David Fitzgerald, Ph.D. Dr. Fitzgerald and his team established that using one of the antibodies, 40H3, as an
Inventors at the National Human Genome Research Institute (NHGRI) discovered that N-acetylmannosamine (ManNAc) can be used for therapeutic purposes. ManNAc therapy given orally shows long-term safety and biochemical efficacy. ManNAc is a small uncharged physiological molecule that crosses membranes